




The relative strengths and weaknesses of Deciphera Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Deciphera Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Deciphera Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 297%, being 84% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	381,096
Cost of Goods Sold	3,732
Intangible Assets	0
Liabilities, Current	100,275
Liabilities, Non-Current	22,375
Other Assets	87,049
Other Compr. Net Income	1,560
Other Expenses	431
Other Liabilities	0
Other Net Income	16,447
Other Revenues	163,356
Property and Equipment	5,421
Research and Development	234,123
Selling, General and Administrative Expense	136,459

Output Variable	Value in 1000 USD
Assets	473,566
Liabilities	122,650
Expenses	374,745
Revenues	163,356
Stockholders Equity	350,916
Net Income	-194,942
Comprehensive Net Income	-194,162
BaseVar	576,162
ECR before LimitedLiability	191%
Economic Capital Ratio	297%